The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 10, 2017

Filed:

Oct. 27, 2010
Applicants:

Martin J. Cannon, Little Rock, AR (US);

Kristina L. Bondurant, Little Rock, AR (US);

Timothy J. O'brien, Little Rock, AR (US);

Inventors:

Martin J. Cannon, Little Rock, AR (US);

Kristina L. Bondurant, Little Rock, AR (US);

Timothy J. O'Brien, Little Rock, AR (US);

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 38/08 (2006.01); A61K 38/10 (2006.01); A61K 38/16 (2006.01); C12N 9/64 (2006.01);
U.S. Cl.
CPC ...
C12N 9/6445 (2013.01); C12N 9/6424 (2013.01); A61K 38/00 (2013.01);
Abstract

Peptides of from about 7 to about 50 amino acid residues in length that have epitopes that bind to more than one HLA class II protein and stimulate CD4+ T cells for treatment of cancer from one of three serine proteases overexpressed in ovarian cancer and other cancers—stratum corneum chymotryptic enzyme, matriptase, and hepsin—are described. Since the peptides bind to more than one HLA class II protein variant, they can be used to treat cancer in most patients of a population having a variety of HLA class II alleles. The peptides can be loaded onto autologous dendritic cells of a cancer patient and infused into the patient to activate a CD4+ and CD8+ T cell response that recognizes tumor cells expressing the peptide antigen.


Find Patent Forward Citations

Loading…